Fidia Farmaceutici launches operations of its Türkiye affiliate, expanding its presence in a key strategic market

Fidia Farmaceutici announces the operational launch of its Türkiye affiliate, established in 2025 as part of the company’s longterm international expansion strategy. With activities now officially underway, the affiliate reinforces Fidia’s commitment to bringing its scientific expertise and high quality solutions to one of the region’s most dynamic and fast-growing healthcare markets.

The Türkiye affiliate will initially focus on Fidia’s Specialty Care portfolio, particularly in infectious diseases, providing effective therapeutic solutions that support patient care and improve health outcomes. The portfolio will also include Joint Care products, an area in which the company has built a solid scientific heritage. For more than three decades, Fidia has been committed to improving the management of musculoskeletal conditions (eg. Osteoarthritis and tendinopathies), combining continuous research with a long-standing leadership in intraarticular hyaluronic acid. This experience has shaped a portfolio of evidence based solutions designed to address joint pain and dysfunction and to support patients in maintaining mobility and quality of life.

“The activation of our  Türkiye affiliate represents an important step in Fidia’s global development,” said  Carlo Pizzocaro, CEO and President of Fidia Farmaceutici.  “A direct presence allows us to be closer to healthcare professionals and patients, ensuring the level of scientific support and service quality that characterizes our company.”

Over the coming months, Fidia plans to progressively expand the local offering, integrating additional products from its wider international portfolio.